EPISODE · Apr 28, 2026 · 30 MIN
Ep. 57 First-Line Therapy for Advanced Hepatocellular Carcinoma: Decisions in the Real World with Dr. A. Craig Lockhart and Dr. Lingling Du
from BackTable Tumor Board · host BackTable Inc.
Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:24 - Early Immunotherapy Momentum07:03 - Long Term Survival Tails14:13 - Autoimmune Disease Nuances22:45 - Combining With Liver Directed Therapy25:29 - Ideal Candidate for Ipi Nivo26:54 - Wrap Up and Takeaways --- More about this episode The doctors discuss key data from IMbrave150 (atezolizumab/bevacizumab vs sorafenib), HIMALAYA (STRIDE: tremelimumab plus durvalumab vs sorafenib), and CheckMate 9DW (ipilimumab/nivolumab vs physician’s choice TKI, largely lenvatinib), noting improved survival, high response rates with ipi/nivo, and long-term survival “tails.” They cover negative/neutral TKI-IO trials (LEAP-002, COSMIC-312) and focus on patient selection nuances including EGD/variceal bleeding risk with bevacizumab, hypertension/proteinuria, platelet thresholds, autoimmune disease considerations, Child-Pugh status, liver function preservation, and preferences when combining systemic therapy with liver-directed procedures like Y90. --- Resources IMbrave150https://www.nejm.org/doi/full/10.1056/NEJMoa1915745 Himalaya Studyhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 CHeckmate 040https://jamanetwork.com/journals/jamaoncology/fullarticle/2771012 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
What this episode covers
Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:24 - Early Immunotherapy Momentum07:03 - Long Term Survival Tails14:13 - Autoimmune Disease Nuances22:45 - Combining With Liver Directed Therapy25:29 - Ideal Candidate for Ipi Nivo26:54 - Wrap Up and Takeaways --- More about this episode The doctors discuss key data from IMbrave150 (atezolizumab/bevacizumab vs sorafenib), HIMALAYA (STRIDE: tremelimumab plus durvalumab vs sorafenib), and CheckMate 9DW (ipilimumab/nivolumab vs physician’s choice TKI, largely lenvatinib), noting improved survival, high response rates with ipi/nivo, and long-term survival “tails.” They cover negative/neutral TKI-IO trials (LEAP-002, COSMIC-312) and focus on patient selection nuances including EGD/variceal bleeding risk with bevacizumab, hypertension/proteinuria, platelet thresholds, autoimmune disease considerations, Child-Pugh status, liver function preservation, and preferences when combining systemic therapy with liver-directed procedures like Y90. --- Resources IMbrave150https://www.nejm.org/doi/full/10.1056/NEJMoa1915745 Himalaya Studyhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 CHeckmate 040https://jamanetwork.com/journals/jamaoncology/fullarticle/2771012 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
NOW PLAYING
Ep. 57 First-Line Therapy for Advanced Hepatocellular Carcinoma: Decisions in the Real World with Dr. A. Craig Lockhart and Dr. Lingling Du
No transcript for this episode yet
Similar Episodes
No similar episodes found.